These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 8167353)
1. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. Storb R; Leisenring W; Deeg HJ; Anasetti C; Appelbaum F; Bensinger W; Buckner CD; Clift R; Doney K; Hansen J Blood; 1994 May; 83(9):2749-50. PubMed ID: 8167353 [No Abstract] [Full Text] [Related]
2. Re: Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versus-host disease. Sorror ML; Leisenring W; Deeg HJ; Martin PJ; Storb R Biol Blood Marrow Transplant; 2005 Jul; 11(7):567-8. PubMed ID: 15983557 [No Abstract] [Full Text] [Related]
3. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Storb R; Deeg HJ; Farewell V; Doney K; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Hansen J Blood; 1986 Jul; 68(1):119-25. PubMed ID: 3521761 [TBL] [Abstract][Full Text] [Related]
4. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Locatelli F; Bruno B; Zecca M; Van-Lint MT; McCann S; Arcese W; Dallorso S; Di Bartolomeo P; Fagioli F; Locasciulli A; Lawler M; Bacigalupo A Blood; 2000 Sep; 96(5):1690-7. PubMed ID: 10961865 [TBL] [Abstract][Full Text] [Related]
5. Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. Storb R; Sanders JE; Pepe M; Anasetti C; Appelbaum FR; Buckner CD; Deeg HJ; Doney K; Hansen J; Martin P Blood; 1991 Aug; 78(4):1144-5. PubMed ID: 1868246 [No Abstract] [Full Text] [Related]
6. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease. Storb R; Deeg HJ; Whitehead J; Farewell V; Appelbaum FR; Beatty P; Bensinger W; Buckner CD; Clift RA; Doney K Transplant Proc; 1987 Feb; 19(1 Pt 3):2608-13. PubMed ID: 3547942 [No Abstract] [Full Text] [Related]
7. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Storb R; Deeg HJ; Pepe M; Doney K; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Hansen J Br J Haematol; 1989 Aug; 72(4):567-72. PubMed ID: 2673331 [TBL] [Abstract][Full Text] [Related]
8. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis. Yagasaki H; Kojima S; Yabe H; Kato K; Kigasawa H; Sakamaki H; Tsuchida M; Kato S; Kawase T; Muramatsu H; Morishima Y; Kodera Y Biol Blood Marrow Transplant; 2009 Dec; 15(12):1603-8. PubMed ID: 19896085 [TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia. Storb R; Martin P; Deeg HJ; Sanders JE; Pepe M; Singer J; Anasetti C; Stewart P; Appelbaum FR; Sullivan KM Blood; 1992 Jun; 79(11):3091-2. PubMed ID: 1586751 [No Abstract] [Full Text] [Related]
10. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Ruutu T; Volin L; Parkkali T; Juvonen E; Elonen E Blood; 2000 Oct; 96(7):2391-8. PubMed ID: 11001889 [TBL] [Abstract][Full Text] [Related]
11. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Gluckman E; Horowitz MM; Champlin RE; Hows JM; Bacigalupo A; Biggs JC; Camitta BM; Gale RP; Gordon-Smith EC; Marmont AM Blood; 1992 Jan; 79(1):269-75. PubMed ID: 1728315 [TBL] [Abstract][Full Text] [Related]
12. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. Storb R; Deeg HJ; Whitehead J; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Doney K; Farewell V N Engl J Med; 1986 Mar; 314(12):729-35. PubMed ID: 3513012 [TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: preliminary results. Horstmann M; Stockschläder M; Krüger W; Hoffknecht M; Betker R; Kabisch H; Zander A Ann Hematol; 1995 Aug; 71(2):77-81. PubMed ID: 7654856 [TBL] [Abstract][Full Text] [Related]
14. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768 [TBL] [Abstract][Full Text] [Related]
15. Bone marrow transplantation in Thailand. Issaragrisil S; Visuthisakchai S; Suvatte V; Chandanayingyong D; Piankijagum A Transplant Proc; 1994 Aug; 26(4):2348-9. PubMed ID: 8066770 [No Abstract] [Full Text] [Related]
16. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Storb R; Pepe M; Anasetti C; Appelbaum FR; Beatty P; Doney K; Martin P; Stewart P; Sullivan KM; Witherspoon R Blood; 1990 Sep; 76(5):1037-45. PubMed ID: 2203481 [TBL] [Abstract][Full Text] [Related]
17. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Sorror ML; Leisenring W; Deeg HJ; Martin PJ; Storb R Biol Blood Marrow Transplant; 2005 Oct; 11(10):814-5. PubMed ID: 16182182 [No Abstract] [Full Text] [Related]
18. Allogeneic bone marrow transplantation for severe aplastic anemia. Speck B Semin Hematol; 1991 Oct; 28(4):319-21. PubMed ID: 1759173 [No Abstract] [Full Text] [Related]
19. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies. Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660 [TBL] [Abstract][Full Text] [Related]
20. Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? Storb R; Leisenring W; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan KM; Witherspoon R; Pettinger M; Bensinger W; Buckner CD; Clift R; Flowers ME; Hansen JA; Pepe M; Chauncey T; Sanders J; Thomas ED Biol Blood Marrow Transplant; 1997 Oct; 3(4):194-201. PubMed ID: 9360781 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]